Promethera raises EUR 20.3M in series C

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) raised EUR 20.3 million ($25.2 million) in a series C round led by existing investor Vesalius BioCapital. New investors included Germany's SMS Group and Belgium's SFPI-FPIM, while existing investors SRIW; Vives-Louvain Tech Transfer Office Fund; Boehringer Ingelheim Venture Fund; Shire plc (LSE:SHP; NASDAQ:SHPG); the Mitsui Global investment unit of Mitsui & Co. Ltd. (Tokyo:8031); Pall Corp. (NYSE:PLL); and angels also participated.

Promethera also secured an additional EUR 5 million ($6.2 million) in government loans and subsidies from the Walloon region of Belgium. ...